{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:45:14Z","timestamp":1783644314406,"version":"3.55.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40265-025-02225-6","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T06:58:24Z","timestamp":1758697104000},"page":"1493-1497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Fosrolapitant\/Palonosetron: First Approval"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0789-7765","authenticated-orcid":false,"given":"Simon","family":"Fung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"2225_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2147\/CE.S65555","volume":"10","author":"L Celio","year":"2015","unstructured":"Celio L, Niger M, Ricchini F, et al. Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy. Core Evid. 2015;10:75\u201387.","journal-title":"Core Evid"},{"issue":"9","key":"2225_CR2","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1200\/JCO-24-01308","volume":"43","author":"H Zhou","year":"2025","unstructured":"Zhou H, Zhao Y, Zhang M, et al. Randomized, phase III trial of mixed formulation of fosrolapitant and palonosetron (HR20013) in preventing cisplatin-based highly emetogenic chemotherapy-induced nausea and vomiting: PROFIT. J Clin Oncol. 2025;43(9):1123\u201336.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2225_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102195","volume":"9","author":"J Herrstedt","year":"2024","unstructured":"Herrstedt J, Clark-Snow R, Ruhlmann CH, et al. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open. 2024;9(2): 102195.","journal-title":"ESMO Open."},{"key":"2225_CR4","unstructured":"Fujian Shengdi Pharmaceutical Co. L. Fosrolapitant and palonosetron hydrochloride for injection (HR20013): Chinese prescribing information. 2025. Accessed 25 June 2025."},{"key":"2225_CR5","unstructured":"National Medical Products Administration. The State Food and Drug Administration approved the marketing of phosphoropitamine and palonosetron for injection. 2025. https:\/\/www.nmpa.gov.cn\/zhuanti\/cxylqx\/cxypxx\/20250529152010114.html. Accessed 8 July 2025."},{"issue":"7","key":"2225_CR6","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1080\/17512433.2019.1621162","volume":"12","author":"M Karthaus","year":"2019","unstructured":"Karthaus M, Schiel X, Ruhlmann CH, et al. Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy-induced nausea and vomiting in adults. Expert Rev Clin Pharmacol. 2019;12(7):661\u201380.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2225_CR7","unstructured":"Hengrui. Hengrui's innovative drug Ritanine\u00ae is approved for the prevention of acute and delayed nausea and vomiting caused by highly emetogenic chemotherapy in adults [media release]. 30 May 2025. https:\/\/www.hengrui.com\/media\/detail-775.html."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02225-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02225-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02225-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T05:31:01Z","timestamp":1761715861000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02225-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":7,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2225"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02225-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. S. Fung is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}